Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
TER
0.49% p.a.
Distribution policy
Accumulating
Replication
Physical
Fund size
EUR 25 m
Inception Date
23 January 2018
Holdings
36
Overview
Description
The L&G Pharma Breakthrough UCITS ETF seeks to track the Solactive Pharma Breakthrough Value index. The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.
Graphique
Basis
Data
| Index | Solactive Pharma Breakthrough Value |
| Investeringsfocus | Equity, World, Health Care |
| Fondsgrootte | EUR 25 m |
| Totale kostenratio (TER) | 0.49% p.a. |
| Replicatie | Fysiek (Volledige replicatie) |
| Juridische structuur | ETF |
| Beleggingsaanpak | Langdurig |
| Duurzaamheid | No |
| Valuta van het fonds | USD |
| Valutarisico | Valuta niet gedekt |
| Volatiliteit 1 jaar (in EUR) | 18.30% |
| Startdatum/Noteringsdatum | 23 January 2018 |
| Distributiebeleid | Accumulerend |
| Distributiefrequentie | - |
| Vestigingsplaats van het fonds | Ireland |
| Fondsaanbieder | Legal & General (LGIM) |
| Fondsstructuur | Public Limited Company |
| UCITS-conformiteit | Yes |
| Administrateur | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Beleggingsadviseur | Legal & General Investment Management Limited |
| Bewaarbank | The Bank of New York Mellon SA/NV, Dublin Branch |
| Revisiebedrijf | Ernst & Young |
| Einde belastingjaar | 30 June |
| Vertegenwoordiger van Zwitserland | First Independent Fund Services LTD |
| Zwitserse uitbetalende instantie | NPB Neue Privat Bank AG |
| Duitsland | 30% tax rebate |
| Zwitserland | ESTV Reporting |
| Oostenrijk | Tax Reporting Fund |
| UK | UK Reporting |
| Italië | 26.0% |
| Indextype | Totale rendementsindex |
| Swap tegenpartij | - |
| Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
| Effectenlening | Yes |
| Tegenpartij die effecten uitleent |
Vergelijkbare ETF
In dit gedeelte vind je informatie over andere ETF met een vergelijkbare beleggingsfocus als de L&G Pharma Breakthrough UCITS ETF
Vergelijkbare ETF via beleggingsgidsen
Wat vind je van ons ETF-profiel? Here you'll find our Questionnaire.
Bedrijven
Hieronder vind je informatie over de samenstelling van de L&G Pharma Breakthrough UCITS ETF
Top 10 holdings
Weging van top 10-holdings
van 36
36.85%
| Xencor, Inc. | 5.74% |
| Travere Therapeutics | 5.58% |
| Halozyme Therapeutics | 3.57% |
| Xeris Biopharma Holdings | 3.33% |
| argenx | 3.32% |
| Ligand Pharmaceuticals, Inc. | 3.17% |
| Jazz Pharmaceuticals | 3.10% |
| Royalty Pharma | 3.07% |
| Incyte Corp. | 3.00% |
| Zevra Therapeutics | 2.97% |
Sectoren
| Healthcare | 97.91% |
| Industrials | 2.02% |
| Other | 0.07% |
Vanaf 27/08/2026
Prestaties
Rendementsoverzicht
| YTD | +7,75% |
| 1 maand | -4,72% |
| 3 maanden | -8,68% |
| 6 maanden | +5,30% |
| 1 jaar | +11,19% |
| 3 jaar | +31,93% |
| 5 jaar | +11,89% |
| Since inception | +54,95% |
| 2025 | +20,92% |
| 2024 | +1,37% |
| 2023 | -13,42% |
| 2022 | -1,53% |
Maandelijks rendement in een heat map
Risico
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risico-overzicht
| Volatiliteit 1 jaar | 18,30% |
| Volatiliteit 3 jaar | 16,77% |
| Volatiliteit 5 jaar | 17,19% |
| Rendement/Risico 1 jaar | 0,61 |
| Rendement/Risico 3 jaar | 0,58 |
| Rendement/Risico 5 jaar | 0,13 |
| Maximaal waardedaling 1 jaar | -11,20% |
| Maximaal waardedaling 3 jaar | -19,94% |
| Maximaal waardedaling 5 jaar | -28,26% |
| Maximaal waardedaling sinds aanvang | -28,95% |
Voortschrijdende volatiliteit over 1 jaar
Beurs
Beursnoteringen
| Beursnotering | Handelsvaluta | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | ETLI | - - | - - | - |
| Borsa Italiana | EUR | BIOT | BIOT IM ETLIEUIV | ECBIOT.MI ETLIEURINAV=SOLA | Flow Traders B.V. |
| Euronext Amsterdam | EUR | BIOT | BIOT NA ETLIEUIV | GOBIOT.AS ETLIEURINAV=SOLA | Flow Traders B.V. |
| London Stock Exchange | GBX | BIGT | BIGT LN NA | BIGT.L NA | Flow Traders B.V. |
| London Stock Exchange | USD | BIOT | BIOT LN NA | GEBIOT.L NA | Flow Traders B.V. |
| SIX Swiss Exchange | CHF | BIOT | BIOT SW ETLIEUIV | BIOTC.S ETLIEURINAV=SOLA | Flow Traders B.V. |
| XETRA | EUR | ETLI | ETLI GY ETLIEUIV | ETLI.DE ETLIEURINAV=SOLA | Flow Traders B.V. |
Further information
Nieuwste artikelen
Frequently asked questions
What is the name of BIOT?
The name of BIOT is L&G Pharma Breakthrough UCITS ETF.
What is the ticker of L&G Pharma Breakthrough UCITS ETF?
The primary ticker of L&G Pharma Breakthrough UCITS ETF is BIOT.
What is the ISIN of L&G Pharma Breakthrough UCITS ETF?
The ISIN of L&G Pharma Breakthrough UCITS ETF is IE00BF0H7608.
What are the costs of L&G Pharma Breakthrough UCITS ETF?
The total expense ratio (TER) of L&G Pharma Breakthrough UCITS ETF amounts to 0.49% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is L&G Pharma Breakthrough UCITS ETF paying dividends?
L&G Pharma Breakthrough UCITS ETF is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.
What's the fund size of L&G Pharma Breakthrough UCITS ETF?
The fund size of L&G Pharma Breakthrough UCITS ETF is 25m Euro. See the following article for more information about the size of ETFs.
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.